Stockscreener 앱 받기
0.7985
4.46%
-0.0373
시간 외 거래:
.84
0.0415
+5.20%
전일 마감가:
$0.8358
열려 있는:
$0.8499
하루 거래량:
315.63K
Relative Volume:
0.15
시가총액:
$12.10M
수익:
$2.73M
순이익/손실:
$-19.43M
주가수익비율:
-0.3512
EPS:
-2.2739
순현금흐름:
$-17.91M
1주 성능:
-36.12%
1개월 성능:
-57.53%
6개월 성능:
-42.96%
1년 성능:
-51.90%
1일 변동 폭
$0.7985
$0.8857
1주일 범위
$0.64
$1.31
52주 변동 폭
$0.64
$3.265
Traws Pharma Inc Stock (TRAW) Company Profile
명칭
Traws Pharma Inc
전화
267-759-3680
주소
12 PENNS TRAIL, NEWTOWN
Compare TRAW vs VRTX, REGN, ARGX, ALNY, RVMD
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
TRAW
Traws Pharma Inc
|
0.7985 | 11.45M | 2.73M | -19.43M | -17.91M | -2.2739 |
VRTX
Vertex Pharmaceuticals Inc
|
458.99 | 114.33B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
607.93 | 64.47B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
892.26 | 54.99B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
282.72 | 38.42B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
157.77 | 34.03B | 742.00K | -1.37B | -1.07B | -7.0731 |
Traws Pharma Inc Stock (TRAW) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-12-03 | 개시 | H.C. Wainwright | Buy |
| 2022-03-01 | 개시 | Ladenburg Thalmann | Buy |
| 2021-05-18 | 개시 | Guggenheim | Buy |
| 2018-03-01 | 재확인 | H.C. Wainwright | Buy |
| 2018-01-17 | 다운그레이드 | Maxim Group | Buy → Hold |
| 2017-10-09 | 개시 | H.C. Wainwright | Buy |
| 2017-04-27 | 개시 | Laidlaw | Buy |
| 2015-07-01 | 업그레이드 | Piper Jaffray | Neutral → Overweight |
| 2015-05-05 | 개시 | H.C. Wainwright | Buy |
모두보기
Traws Pharma Inc 주식(TRAW)의 최신 뉴스
Bandwidth, Traws Pharma and other big stocks moving lower in Monday's pre-market session - MSN
Traws Pharma stock falls as UK regulator delays key flu study - MSN
TRAW Downgraded by Ladenburg Thalmann -- Rating Changed to Neutr - GuruFocus
Traws Delays Influenza Study After UK Regulatory Setback - MyChesCo
Traws Pharma Stock Falls As UK Regulator Delays Key Flu Study - Benzinga
Bandwidth, Traws Pharma And Other Big Stocks Moving Lower In Monday's Pre-Market Session - Benzinga
Micron, Nebius surge premarket; Traws Pharma tumbles By Investing.com - Investing.com Australia
Traws Pharma Shares Slide After UK Regulator Postpones Influenza Study - Yahoo Finance
Why is Traws Pharma stock tumbling today? By Investing.com - Investing.com Canada
Traws Pharma stock tumbles after UK regulator delays flu trial By Investing.com - Investing.com Canada
Traws Pharma gains after hantavirus drug development update amid cruise ship outbreak - MSN
Traws Pharma Defers Phase 2a Human Influenza Study After UK MHRA Review, Advances Alternative Antiviral Candidates 1 – Minichart - Minichart
Traws Pharma (TRAW) Delays Phase 2a Trial of Tivoxavir Marboxil - GuruFocus
Why Did TRAW Stock Slump 28% After Hours? - Asianet Newsable
Traws Pharma Defers Phase 2a Influenza Study Plans - TipRanks
Traws Pharma Defers Phase 2a Study of Tivoxavir Marboxil Following UK Regulatory Review - Quiver Quantitative
Traws Pharma Provides Regulatory Update on Influenza Program | Associated Press | syndication news - Enidnews.com
Regulator setback stalls Traws Pharma bird flu drug test in humans - Stock Titan
Traws Pharma (NASDAQ: TRAW) defers Phase 2a influenza study, advances backup antivirals with runway to Q1 2027 - Stock Titan
Traws Pharma (TRAW) Finds Support, Edges Higher With Modest GainContinuation Pattern Picks - newsline.com
Traws Pharma, Inc. (TRAW) forms 'hammer chart pattern': Time for bottom fishing? - MSN
Traws Pharma (TRAW) Edges Lower as Stock Consolidates Near Key SupportBPI Bear Correction - newsline.com
TRAWS PHARMA INC (TRAW) Stock Chart - ChartMill
Traws Pharma Q1 2026 Earnings: EPS Surprise Beats Estimates Despite No Revenue, Stock Declines 7.4%SaaS Earnings Trends - newsline.com
Traws Pharma Dips as Company Expands Outbreak Drug Play - Bez Kabli
Traws Pharma (TRAW) Holds Near Key Support Amid Modest UptickVolume Nodes - newsline.com
TRAW | Traws Pharma, Inc. Common Executive Compensation - Quiver Quantitative
Traws Pharma Q1 2026 Earnings: Narrower-Than-Expected Loss Fails to Lift StockEstimate Accuracy - The Legal Advocate
Traws Pharma (NASDAQ: TRAW) 2026 proxy seeks share plan and warrant approvals - Stock Titan
Newtown-based Traws Pharma advances experimental antiviral therapy - Pennsylvania Business Report -
TRAW Q1 2026 Earnings: Narrower-than-Expected Loss Surprises on Lower ExpensesEarnings Recovery Stocks - The Legal Advocate
Traws Pharma announces new antiviral program - BioWorld News
TRAW Advances Novel Anti-Viral Agent for Hantavirus and Ebola - GuruFocus
Traws Pharma Advances Broad-Spectrum Antiviral for Emerging Outbreaks - TipRanks
Traws Pharma Advances Novel Broad-Spectrum Antiviral Agent Targeting Hantavirus, Ebola, and Lassa with Innovative Dual-Strike Mechanism - Quiver Quantitative
Traws Pharma (NASDAQ: TRAW) advances broad antiviral for Hantavirus, Ebola - Stock Titan
Traws Pharma Announces Antiviral Program Targeting Ongoing Hantavirus and Ebola Virus Disease Outbreaks - GlobeNewswire
Traws Pharma, Inc. Files Form 8-K with SEC – Company Details, Address, and Legal Opinion Included - Minichart
TRAW - Finviz
Traws Pharma Updates ATM Equity Offering Prospectus Supplements - TipRanks
Traws Pharma launches $3.13M ATM sales under $50M shelf with Citizens JMP - TradingView
Traws Pharma (NASDAQ: TRAW) outlines $3,128,399 baby shelf ATM capacity - Stock Titan
Traws Pharma (TRAW) Stock Forecast & Analyst Ratings - Moomoo
Traws Pharma Inc. (TRAW) Q1 2026 Earnings: Narrower Net Loss Beats Estimates as Clinical Pipeline AdvancesGuidance Revision Trend - The Legal Advocate
Traws Pharma Q1 2026 Earnings: Narrowed Loss Surpasses Expectations Amid Pre-Revenue StageEarnings Growth Forecast - The Legal Advocate
Traws Pharma Inc. (TRAW) Q1 2026 Earnings: Better-than-Expected Losses Highlight Cost Discipline Amid Pre-Revenue PhaseElite Trading Signals - Newser
Traws Pharma Q1 2026 Earnings: Narrower Than Expected Loss Despite No RevenueSaaS Earnings Trends - The Legal Advocate
Traws Extends Runway With Financing as Flu Trial Nears - MyChesCo
Traws Pharma Inc files for offering of up to $3.1 million in common stock - marketscreener.com
Traws Pharma Inc Files For Offering Of Up To $3.1 Million In Common Stock - TradingView
TRAW (NASDAQ: TRAW) expands ATM by $3.13M under Citizens JMP agreement - Stock Titan
Traws Pharma Inc (TRAW) 재무 분석
매출
순이익
현금흐름
주당 순 이익
2.60%
0.94%
자본화:
|
볼륨(24시간):